287 related articles for article (PubMed ID: 21979953)
1. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
[TBL] [Abstract][Full Text] [Related]
2. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
[TBL] [Abstract][Full Text] [Related]
3. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.
Spangler JB; Manzari MT; Rosalia EK; Chen TF; Wittrup KD
J Mol Biol; 2012 Sep; 422(4):532-44. PubMed ID: 22706026
[TBL] [Abstract][Full Text] [Related]
4. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage.
Eggel A; Baumann MJ; Amstutz P; Stadler BM; Vogel M
J Mol Biol; 2009 Oct; 393(3):598-607. PubMed ID: 19683003
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
6. Selection and characterization of Her2 binding-designed ankyrin repeat proteins.
Zahnd C; Pecorari F; Straumann N; Wyler E; Plückthun A
J Biol Chem; 2006 Nov; 281(46):35167-75. PubMed ID: 16963452
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
8. DARPins: a true alternative to antibodies.
Stumpp MT; Amstutz P
Curr Opin Drug Discov Devel; 2007 Mar; 10(2):153-9. PubMed ID: 17436550
[TBL] [Abstract][Full Text] [Related]
9. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.
Koefoed K; Steinaa L; Søderberg JN; Kjær I; Jacobsen HJ; Meijer PJ; Haurum JS; Jensen A; Kragh M; Andersen PS; Pedersen MW
MAbs; 2011; 3(6):584-95. PubMed ID: 22123060
[TBL] [Abstract][Full Text] [Related]
10. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Jhawer M; Goel S; Wilson AJ; Montagna C; Ling YH; Byun DS; Nasser S; Arango D; Shin J; Klampfer L; Augenlicht LH; Perez-Soler R; Mariadason JM
Cancer Res; 2008 Mar; 68(6):1953-61. PubMed ID: 18339877
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2.
Jost C; Schilling J; Tamaskovic R; Schwill M; Honegger A; Plückthun A
Structure; 2013 Nov; 21(11):1979-91. PubMed ID: 24095059
[TBL] [Abstract][Full Text] [Related]
13. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
16. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display.
Steiner D; Forrer P; Plückthun A
J Mol Biol; 2008 Oct; 382(5):1211-27. PubMed ID: 18706916
[TBL] [Abstract][Full Text] [Related]
17. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
[TBL] [Abstract][Full Text] [Related]
18. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.
Chang KH; Kim MS; Hong GW; Shin YN; Kim SH
Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
[TBL] [Abstract][Full Text] [Related]
20. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
